Freeline Therapeutics Rings the Nasdaq Opening Bell in Celebration of its IPO
Freeline Therapeutics Holdings plc (“Freeline”), a UCL Technology Fund portfolio company focused on innovative liver directed gene therapies for bleeding disorders and other chronic diseases has made a Nasdaq debut (Nasdaq: FRLN). In honor of the occasion, Theresa Heggie, CEO, rang the Opening Bell in a virtual bell ringing ceremony.
The company was founded in 2015, based on the research of Professor Amit Nathwani of the UCL Cancer Institute.
Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of patients suffering from inherited systemic debilitating diseases, announced the pricing of its initial public offering in the United States of 8,823,529 American Depositary Shares (“ADSs”) representing 8,823,529 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of approximately $158.8 million.
Freeline's Nasdaq listing is the 3rd IPO for the UCL Technology Fund since its inception in 2016.